Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $3.3 million.

  • TransMedics' Current Deferred Revenue rose 5132.78% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 5132.78%. This contributed to the annual value of $1.7 million for FY2024, which is 1116.78% down from last year.
  • Latest data reveals that TransMedics reported Current Deferred Revenue of $3.3 million as of Q3 2025, which was up 5132.78% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Current Deferred Revenue ranged from a high of $3.3 million in Q3 2025 and a low of $226000.0 during Q3 2022
  • Its 5-year average for Current Deferred Revenue is $1.2 million, with a median of $473000.0 in 2021.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first tumbled by 7624.35% in 2021, then skyrocketed by 106327.43% in 2023.
  • Quarter analysis of 5 years shows TransMedics' Current Deferred Revenue stood at $250000.0 in 2021, then decreased by 3.6% to $241000.0 in 2022, then skyrocketed by 713.69% to $2.0 million in 2023, then fell by 11.17% to $1.7 million in 2024, then soared by 89.72% to $3.3 million in 2025.
  • Its Current Deferred Revenue stands at $3.3 million for Q3 2025, versus $1.6 million for Q2 2025 and $2.1 million for Q1 2025.